From: Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
HLA Class I | A | B | Bw | C | Cw | |||
Patient 1 | 24:XX | 07:XX | 06:XX | 04:XX | 04:XX | |||
29:XX | 35:XX | 06:XX | 07:XX | 07:XX | ||||
Patient 2 | 11:01 | 27:05 | 04:XX | 01:02 | ||||
24:02 | 35:01 | 06:XX | 04:01 | |||||
HLA Class II | DRB1 | DRB3 | DRB4 | DRB5 | DQB1 | DQA1 | DPB1 | DRw |
Patient 1 | 04:XX | 01:XX | 01:XX | 03:XX | 53:XX | |||
15:XX | 05:XX | 51:XX | ||||||
Patient 2 | 01:01 | 01:03 | 03:02 | 01:01 | 03:01 | |||
04:04 | 53:XX | 05:01 | 03:01 | 14:01 |